3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
3 citations
,
January 2019 in “Bulgarian Journal of Veterinary Medicine” The cat was put to sleep due to recurring infections.
3 citations
,
May 2018 in “Experimental Dermatology” Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
2 citations
,
September 2023 in “JMIR. Journal of medical internet research/Journal of medical internet research” Machine learning can predict symptoms and quality of life in chronic skin disease patients using smartphone app data, and shows that app use varies with patient characteristics.
2 citations
,
January 2012 in “Journal für Kardiologie (Krause & Pachernegg GmbH)” Hirsutism and alopecia during menopause can be diagnosed and treated with specific hormonal and topical therapies.
1 citations
,
September 2025 in “PLOS Digital Health” Large language models often give biased or inaccurate medical responses, especially for LGBTQIA+ prompts.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
1 citations
,
September 2023 in “Dermatology and therapy” More research is needed to find the best treatment for dissecting cellulitis of the scalp.
1 citations
,
January 2023 in “Skin appendage disorders” Hair oils can worsen seborrheic dermatitis in black patients.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
December 2022 in “Research Square (Research Square)” Certain health conditions and hair care habits affect the treatment results for a scalp condition called Central Centrifugal Cicatricial Alopecia.
1 citations
,
September 2022 in “JMIR dermatology” Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
March 2026 in “Frontiers in Pharmacology” New treatments for hair loss show promise but need more testing for effectiveness and safety.
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Alopecia areata negatively affects self-esteem, relationships, and academics in young people.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
October 2025 in “Dermatology and Therapy” Recognizing and treating related skin conditions can improve atopic dermatitis management.
Spironolactone is effective and safe for treating acne.
March 2025 in “SKIN The Journal of Cutaneous Medicine”